Clinical trials are an indispensable link in the development and marketing of new drugs. The “Clinical Trial Accelerator”, which was first set up in Shanghai, was officially released at the Shanghai Biomedical Industry and Medicine Docking Meeting held recently. Through this innovation, the average start time of clinical trials will be reduced from the current 6-13 months to 3-5 months.
Shanghai is a medical center city in China, as well as an important city of biomedical industry. In 2020, a total of 12 biomedical enterprises in Shanghai have been listed on the Science and Technology Innovation Board, and 41 kinds of drugs developed, introduced and produced by biomedical enterprises in Shanghai have been included in the National Directory of Medical Insurance. The Yangtze River Delta Sub-Center for Drug Evaluation and Inspection of State Food and Drug Administration and the Yangtze River Delta Sub-Center for Medical Device Technology Evaluation and Inspection have also announced their listing in Shanghai.
Quality medical resources, how to effectively interact with the development of biomedical industry, is a problem that Shanghai has been exploring to solve. Established and released by Shanghai Shenkang Hospital Development Center, the “Medical Enterprise Research Innovation Platform — Clinical Trial Accelerator” continuously improves the efficiency of biomedical research and development by connecting the needs and resources of enterprises and hospitals.
Qian Biyun, director of the clinical research and development center of Shenkang Hospital Development Center, said that key biomedical projects, recommended by leading industry departments, can be given priority to enter Shanghai municipal hospitals for clinical trials. The accelerator will change the original series mode of finding hospitals offline, and form a parallel mode of receiving information online at the same time after overall management. It is expected that the average start time of clinical trials will be shortened from 6-13 months to 3-5 months.
Biomedical development not only needs technical support, but also needs to solve financing problems. Biomedical enterprises, especially those in the initial stage, are generally asset-light, and it is often difficult to obtain financial support through traditional evaluation standards, which has become a bottleneck restricting the development of enterprises.
At the docking meeting, the financing service of “new drug loan” was officially unveiled, which was the first guarantee fund “batch loan” for biomedical enterprises launched in Shanghai. According to the signed credit agreement, under the policy-based guarantee, the loan underwriting bank will provide a line of credit of 500 million yuan to provide credit support for about 20 biomedical enterprises in the first batch, effectively alleviating the financing difficulties.